Developer docs
API playgroundTry for free, no card

Search company profiles

CastleVax

Full company profile

uuid0002zvm

Namestring
CastleVax
Legal namestring
CastleVax Inc.
Websiteurl
castlevax.com
Company typeenum
Private
Founded yearint
2022
Descriptiontext

CastleVax Inc. is a clinical-stage vaccine research and development company headquartered in New York City, founded in August 2022 as a spin-out from the Mount Sinai Health System. The company's core technology is a Newcastle Disease Virus (NDV)-based vaccine platform — a live, attenuated avian paramyxovirus engineered to express stabilized antigenic proteins — which is licensed exclusively from the Icahn School of Medicine at Mount Sinai and uses HexaPro spike protein technology (six proline substitutions) licensed from UT Austin. CastleVax's lead product is CVAX-01, an intranasal NDV-vectored COVID-19 vaccine candidate designed to induce both systemic and mucosal immunity, including secretory IgA at the respiratory portal of entry. The company also has licensed products distributed internationally (Patria in Mexico via Avimex with Emergency Use Authorization; HXP-GPOVac in Thailand via GPO with full regulatory approval) and a pipeline targeting RSV, HMPV, norovirus, and additional pandemic pathogens.

CastleVax operates a licensing and government-procurement business model rather than direct commercialization. Revenue streams are structured around licensing its platform technology to regional vaccine manufacturers (GPO Thailand, IVAC Vietnam, Avimex Mexico, Instituto Butantan Brazil) for local production using egg-based manufacturing infrastructure, supplemented by government grants and contracts — most notably a BARDA Project NextGen award valued at up to $338 million to advance CVAX-01 through Phase 2b clinical efficacy testing in 10,000 participants. The company serves governments and public health authorities (its primary customer segment) seeking vaccine supply security and pandemic preparedness, as well as high-risk individuals (65+ and immunocompromised) in need of mucosal immunity. Distribution occurs exclusively through technology transfer and licensing channels rather than direct sales.

The company is led by CEO/CSO Michael A. Egan, Ph.D. (25+ years of vaccine R&D experience from Gates MRI, Takeda, Profectus, and Wyeth) and co-founded by globally recognized Mount Sinai scientists Peter Palese, Adolfo García-Sastre, Florian Krammer, and Weina Sun. Board representation includes Mount Sinai Health System executives (Erik Lium as Board Chair; Stephen Harvey as CFO of MSHS; Matt Rosamond as CFO of Icahn School of Medicine). H.C. Wainwright & Co. serves as financial and capital markets advisor. With 1-10 employees, CastleVax remains a capital-efficient, science-driven organization whose valuation thesis depends on Phase 2b/3 clinical success and ultimate regulatory approval of its intranasal vaccine platform.

Short descriptiontext

CastleVax is a clinical-stage biotechnology company developing a Newcastle Disease Virus-based mucosal vaccine platform, with lead candidate CVAX-01 — an intranasal COVID-19 vaccine — licensed from Mount Sinai and funded primarily by BARDA for global government and LMIC distribution.

Operating statusenum
Operating
Ownership categoryenum
Headcount rangeband
1–10
akta.pro rankint
HeadquartersNew York, United States
HQ citystring
New York
HQ countrystring
United States
HQ regionstring
North America
Markets served

Serves global market

Offices1 record

Each record includes

City, Country, Type, Description, Source

Keyword5 values
mucosal vaccine platform, NDV vector technology, intranasal COVID-19 vaccine, clinical-stage biotechnology, pandemic preparedness vaccines
Industry3 codes
PRIMARYHLAAAEAD
Vaccine Technology Platforms (mRNA, viral vector, protein subunit, inactivated/live-attenuated, VLP, DNA)
Healthcare & Life Sciences/Biotechnology & Biologics/Vaccines & Immunization Biologics
SECONDARYHLAAAEAA
Prophylactic Human Vaccines (routine, pediatric, adult)
Healthcare & Life Sciences/Biotechnology & Biologics/Vaccines & Immunization Biologics
SECONDARYHLAAAEAJ
Vaccine Fill-Finish, Packaging & Cold-Chain Formulation (vial/syringe, lyophilization, thermostable)
Healthcare & Life Sciences/Biotechnology & Biologics/Vaccines & Immunization Biologics
NAICS code1 code
  • Pharmaceutical Preparation Manufacturing325412
SIC code1 code
  • Pharmaceutical Preparations2834
Product category
Biotechnology
Social media profiles2 records
GTM motion2 records

Each record includes

Type, Description, Source

Revenue model2 records
1Vaccine Development and Licensing
TypeLicensing Royalties
Description

CastleVax is a clinical-stage vaccine platform company focused on developing and commercializing the NDV-based vaccine platform technology. Revenue will come from licensing the platform technology to manufacturers, government procurement contracts, and potential product sales upon regulatory approval.

castlevax.com
2Government Contracts and Grants
TypeProfessional Services
Description

CastleVax receives significant funding from government sources including BARDA Project NextGen awards (up to $338 million) and state-level biodefense funds for advancing clinical development of COVID-19 and future pandemic vaccines.

castlevax.com
Marketing channels3 records

Each record includes

Title, Type, Stage, Description, Source

Distribution channels2 records

Each record includes

Title, Type, Scope, Target buyer, Description, Source

Cost components4 values
Technology or R&D, Personnel, Operations, Others
GTM typeB2B
B2B
Offering typeServices
Services
Brand1 of 2 records shown
1CVAX-01
Description

Next-generation intranasal COVID-19 vaccine candidate using Newcastle Disease Virus (NDV) vector technology with HexaPro spike protein.

castlevax.com
+1 more record
Core offering1 text field

CastleVax is a clinical-stage vaccine platform company that develops and licenses mucosal (intranasal) vaccines built on the Newcastle Disease Virus (NDV) vector platform expressing stabilized antigens such as HexaPro spike protein. Its lead candidate CVAX-01 targets COVID-19 and is in Phase 2 clinical testing, while the broader NDV platform supports a pipeline of respiratory and pandemic-preparedness vaccines licensed to international manufacturers in Thailand, Vietnam, Brazil, and Mexico.

Differentiator
Functional benefit
Problem solved
Quantifiable outcome1 of 4 values shown
  • In Phase 1/2 studies, NDV-HXP-S performed as well as Pfizer/BioNtech vaccine and outperformed AstraZeneca vaccine in immunogenicity
+3 more records
Product overview1 text field

CastleVax is a clinical-stage vaccine company with a platform-plus-products architecture. The core technology is the Newcastle Disease Virus (NDV) vaccine platform, which produces live attenuated mucosal vaccines. The primary product is CVAX-01, a next-generation intranasal COVID-19 vaccine, alongside NDV-HXP-S (an alternative COVID-19 formulation). The company also has licensed products (Patria in Mexico, HXP-GPOVac in Thailand) and a robust pipeline including bivalent RSV+HMPV and Norovirus mucosal vaccines, plus a broader pandemic preparedness program targeting multiple viral pathogens.

Product and service8 records
1CVAX-01
Categorycore product
Description

Next-generation, live, attenuated, Newcastle Disease Virus (NDV)-vectored intranasal COVID-19 vaccine candidate expressing a stabilized SARS-CoV-2 spike protein using HexaPro technology. Designed to elicit mucosal immunity and protect against SARS-CoV-2 breakthrough infection and transmission. Currently in Phase 2 clinical testing.

2NDV-HXP-S
Categorycore product
Description

COVID-19 booster vaccine utilizing Newcastle Disease Virus vector technology expressing stabilized SARS-CoV-2 spike protein with HexaPro technology. Available as live attenuated (intranasal/intramuscular) and inactivated (intramuscular) formulations. Demonstrated safety profile and low reactogenicity in multiple Phase 1, 2, and 3 clinical trials.

3NDV Vaccine Platform
Categoryplatform
Description

Live, attenuated Newcastle Disease Virus (NDV)-based vaccine platform for developing mucosal vaccines. Enables rapid development of safe and highly immunogenic viral vectors using efficient mucosal delivery, with no pre-existing immunity in humans, flexible genome capacity up to 5kb, and bilipid membrane for foreign antigen incorporation. Supports monovalent, bivalent, or multivalent formulations. Licensed from Mount Sinai on an exclusive basis.

4Patria (AVX/COVID-12)
Categorylicensed product
Description

NDV-based COVID-19 vaccine developed by Laboratorio Avimex under license from CastleVax. Received Emergency Use Authorization in Mexico from COFEPRIS. Phase 3 results demonstrated effectiveness as a booster vaccine generating neutralizing antibodies comparable to WHO-approved vaccine comparator.

5HXP-GPOVac
Categorylicensed product
Description

NDV-HXP-S COVID-19 vaccine produced by Thailand's Government Pharmaceutical Organization (GPO). Inactivated formulation produced using egg-based technology. Received conditional approval for emergency use in Thailand as a booster for adults 18 years and older, marking the first domestically produced COVID-19 vaccine in Thailand.

6Bivalent RSV+HMPV Vaccine
Categorypipeline product
Description

Mucosal vaccine candidate targeting Respiratory Syncytial Virus (RSV) and Human Metapneumovirus (HMPV) in development as part of CastleVax's pipeline of respiratory virus mucosal vaccines.

7Mucosal Norovirus Vaccine
Categorypipeline product
Description

Mucosal vaccine candidate targeting Norovirus in development as part of CastleVax's pipeline of mucosal vaccines for respiratory and enteric pathogens.

8Pandemic Preparedness Pipeline
Categorypipeline
Description

NDV platform engineered to express antigens from emerging and endemic viruses including SARS-CoV-2, RSV, HMPV, CMV, HBV, HCV, Arenaviruses (Lassa), Filoviruses (Ebola), Nipah Virus, Hendra Virus, Chikungunya, Rift Valley Fever, Hantavirus, and Highly Pathogenic Avian Influenza for pandemic preparedness.

Scale indicator7 records

Each record includes

Type, Value, Description, Source

Partnership7 partners
Strategic tierCoreTypeTechnology or Integration
Description

AptarGroup provides nasal vaccine delivery solutions (LuerVax® and Spray Divider™) utilized in CastleVax's Phase II clinical trial of CVAX-01. Their regulatory and technical expertise supports next-generation nasal vaccine delivery development.

Strategic tierCoreTypeStrategic or Co-development Partner
Description

Mount Sinai developed the NDV-vectored vaccine platform technology through scientists Peter Palese, Adolfo García-Sastre, Florian Krammer, and Weina Sun. Licensed exclusively to CastleVax for commercial development. Mount Sinai holds a financial interest in CastleVax and is represented on the Board of Directors.

Strategic tierCoreTypeTechnology or Integration
Description

UT Austin developed the HexaPro spike protein technology (6 proline stabilizing mutations) used in CastleVax's vaccines. Licensed on a non-exclusive basis to CastleVax. The same team previously developed spike proteins used in several approved COVID-19 vaccines globally.

Strategic tierMajorTypeOEM/ Whitelabel/ Licensing Partner
Description

Avimex licensed CastleVax's NDV-based vaccine technology to develop Patria® (AVX/COVID-12) COVID-19 vaccine. Completed Phase 3 clinical trials showing effectiveness as a booster comparable to WHO-approved vaccine. Received Emergency Use Authorization in Mexico. Project financed by Conacyt (Mexican National Council of Science and Technology).

Strategic tierMajorTypeOEM/ Whitelabel/ Licensing Partner
Description

GPO licensed the NDV-HXP-S vaccine technology for domestic production in Thailand. Completed Phase 3 clinical evaluation with 4,000 volunteers. Received conditional approval for emergency use - the first domestically produced COVID-19 vaccine in Thailand. Manufacturing capacity of 5-10 million doses annually.

6Institute of Vaccines and Medical Biologicals (IVAC) Vietnam
Strategic tierMajorTypeOEM/ Whitelabel/ Licensing Partner
Description

IVAC licensed the NDV-HXP-S vaccine (COVIVAC) for production in Vietnam. Phase 2 results showed higher concentration of neutralizing antibodies compared to AstraZeneca vaccine. Phase 3 clinical trials in planning.

castlevax.com
7PATH
Strategic tierMajorTypeStrategic or Co-development Partner
Description

PATH served as connector, facilitator, and technical advisor for the international NDV-HXP-S vaccine consortium. With funding from CEPI, PATH supported consortium efforts aligned with advancing immunization equity. Supported vaccine development in Thailand, Vietnam, and Brazil.

castlevax.com
Recent move7 records

Each record includes

Date, Type, Title, Description, Source

Expansion highlight5 records

Each record includes

Type, Description

Peers10 records
TypeOthers
Description

Vaccine contract development and manufacturing organization with mucosal vaccine expertise and government/biodefense relationships analogous to CastleVax's BARDA-funded development model.

TypeDirect peer
Description

Clinical-stage vaccine developer using bovine and avian paramyxovirus vectors (closely related to NDV) for intranasal mucosal vaccines, including RSV and COVID-19 candidates. Directly comparable platform approach and mucosal delivery focus targeting respiratory pathogens.

TypeDirect peer
Description

Clinical-stage vaccine company using live-attenuated viral vector platforms (including intranasal formulations) to develop vaccines against influenza, RSV, and other respiratory viruses. Shares CastleVax's live-attenuated intranasal mucosal vaccine thesis.

TypeDirect peer
Description

Clinical-stage biotech developing intranasal live-attenuated vaccines for RSV and other respiratory viruses, with similar small team, mucosal immunity focus, and clinical-stage profile comparable to CastleVax.

TypeDirect peer
Description

Developer of M2SR intranasal influenza vaccine, sharing CastleVax's intranasal respiratory vaccine positioning and clinical-stage development profile.

TypeEmerging player
Description

Clinical-stage biotech developing vaccines for infectious diseases and chronic conditions. CastleVax's Director of Clinical Operations previously led vaccine trials at Vaxxinity, reflecting overlapping talent pool and clinical operations approach.

TypeBroad incumbent
Description

Large global vaccine manufacturer with multiple platform technologies (including intranasal and viral vector vaccines) serving LMIC markets, comparable to CastleVax's licensed manufacturing partners in India-adjacent emerging markets.

TypeBroad incumbent
Description

Established commercial-stage vaccine developer with COVID-19 and influenza candidates using protein subunit and matrix-M adjuvant platforms. Competes with CastleVax for the same next-generation COVID-19 booster market.

TypeBroad incumbent
Description

Dominant mRNA COVID-19 vaccine manufacturer and BARDA Project NextGen recipient, representing the entrenched standard-of-care comparator against which CastleVax's CVAX-01 is being tested.

TypeBroad incumbent
Description

mRNA vaccine leader with Pfizer-partnered COVID-19 vaccine that serves as the primary comparator and standard-of-care threat to CastleVax's intranasal COVID-19 booster strategy.

Market position
Strengths4 records

Each record includes

Headline, Details, Source

Weaknesses4 records

Each record includes

Headline, Details, Source

Competitive moat5 records

Each record includes

Type, Details

Key risks6 records

Each record includes

Headline, Details, Source

Key highlights6 records

Each record includes

Headline, Details, Source

Customer concentration

Classification, Details

Named customers4 records

Each record includes

Name, Industry, Type, Use case, Source, UUID

Segment3 records

Each record includes

Title, Type, Primary, Description, Pain point addressed, Use case, Source

Ideal customer profile3 records

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

Technology focused
Yes
API detail
Has APIbool
No

Docs URL, Description

AI maturity
App detail

Has app

Feature4 records

Each record includes

Title, Differentiator, Description, Source

Core technology
Revenue estimate
Valuation estimate
Number of profiles
Profiles11 records

Each record includes

Name, Designation, Designation category, Overview, Profile commentary, Source

No data
Compliance3 records

Each record includes

Name, Class, Description

Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds1 record

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors1 record

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

CastleVax

Biotechnologycastlevax.com

CastleVax is a clinical-stage biotechnology company developing a Newcastle Disease Virus-based mucosal vaccine platform, with lead candidate CVAX-01 — an intranasal COVID-19 vaccine — licensed from Mount Sinai and funded primarily by BARDA for global government and LMIC distribution.

What CastleVax does

CastleVax Inc. is a clinical-stage vaccine research and development company headquartered in New York City, founded in August 2022 as a spin-out from the Mount Sinai Health System. The company's core technology is a Newcastle Disease Virus (NDV)-based vaccine platform — a live, attenuated avian paramyxovirus engineered to express stabilized antigenic proteins — which is licensed exclusively from the Icahn School of Medicine at Mount Sinai and uses HexaPro spike protein technology (six proline substitutions) licensed from UT Austin. CastleVax's lead product is CVAX-01, an intranasal NDV-vectored COVID-19 vaccine candidate designed to induce both systemic and mucosal immunity, including secretory IgA at the respiratory portal of entry. The company also has licensed products distributed internationally (Patria in Mexico via Avimex with Emergency Use Authorization; HXP-GPOVac in Thailand via GPO with full regulatory approval) and a pipeline targeting RSV, HMPV, norovirus, and additional pandemic pathogens.

CastleVax operates a licensing and government-procurement business model rather than direct commercialization. Revenue streams are structured around licensing its platform technology to regional vaccine manufacturers (GPO Thailand, IVAC Vietnam, Avimex Mexico, Instituto Butantan Brazil) for local production using egg-based manufacturing infrastructure, supplemented by government grants and contracts — most notably a BARDA Project NextGen award valued at up to $338 million to advance CVAX-01 through Phase 2b clinical efficacy testing in 10,000 participants. The company serves governments and public health authorities (its primary customer segment) seeking vaccine supply security and pandemic preparedness, as well as high-risk individuals (65+ and immunocompromised) in need of mucosal immunity. Distribution occurs exclusively through technology transfer and licensing channels rather than direct sales.

The company is led by CEO/CSO Michael A. Egan, Ph.D. (25+ years of vaccine R&D experience from Gates MRI, Takeda, Profectus, and Wyeth) and co-founded by globally recognized Mount Sinai scientists Peter Palese, Adolfo García-Sastre, Florian Krammer, and Weina Sun. Board representation includes Mount Sinai Health System executives (Erik Lium as Board Chair; Stephen Harvey as CFO of MSHS; Matt Rosamond as CFO of Icahn School of Medicine). H.C. Wainwright & Co. serves as financial and capital markets advisor. With 1-10 employees, CastleVax remains a capital-efficient, science-driven organization whose valuation thesis depends on Phase 2b/3 clinical success and ultimate regulatory approval of its intranasal vaccine platform.

CastleVax firmographics

Firmographics
Name
CastleVax
Legal name
CastleVax Inc.
Website
https://castlevax.com
Company type
Private
Founded year
2022
Operating status
Operating
Headcount range
1–10 employees
Short description
CastleVax is a clinical-stage biotechnology company developing a Newcastle Disease Virus-based mucosal vaccine platform, with lead candidate CVAX-01 — an intranasal COVID-19 vaccine — licensed from Mount Sinai and funded primarily by BARDA for global government and LMIC distribution.
Ownership category
akta.pro rank

CastleVax industry classification

Industry
Product category
Biotechnology
NAICS
Pharmaceutical Preparation Manufacturing (325412)
SIC
Pharmaceutical Preparations (2834)
akta.pro industry
PRIMARYHLAAAEAD
Vaccine Technology Platforms (mRNA, viral vector, protein subunit, inactivated/live-attenuated, VLP, DNA)
Healthcare & Life Sciences/Biotechnology & Biologics/Vaccines & Immunization Biologics
SECONDARYHLAAAEAA
Prophylactic Human Vaccines (routine, pediatric, adult)
Healthcare & Life Sciences/Biotechnology & Biologics/Vaccines & Immunization Biologics
SECONDARYHLAAAEAJ
Vaccine Fill-Finish, Packaging & Cold-Chain Formulation (vial/syringe, lyophilization, thermostable)
Healthcare & Life Sciences/Biotechnology & Biologics/Vaccines & Immunization Biologics

Keywords

  • Mucosal vaccine platform
  • NDV vector technology
  • Intranasal COVID-19 vaccine
  • Clinical-stage biotechnology
  • Pandemic preparedness vaccines

Where CastleVax is headquartered

Location

Headquarters

HQ city
New York
HQ country
United States
HQ region
North America

Offices1 record

Markets served

CastleVax business model

Business model
GTM type
B2B
Offering type
Services
Cost components
Technology or R&D, Personnel, Operations, Others

Revenue model

  1. Vaccine Development and Licensing: CastleVax is a clinical-stage vaccine platform company focused on developing and commercializing the NDV-based vaccine platform technology. Revenue will come from licensing the platform technology to manufacturers, government procurement contracts, and potential product sales upon regulatory approval.
  2. Government Contracts and Grants: CastleVax receives significant funding from government sources including BARDA Project NextGen awards (up to $338 million) and state-level biodefense funds for advancing clinical development of COVID-19 and future pandemic vaccines.

Go-to-market motion2 records

Distribution channels2 records

Marketing channels3 records

CastleVax product offering

Product offering

Core offering

CastleVax is a clinical-stage vaccine platform company that develops and licenses mucosal (intranasal) vaccines built on the Newcastle Disease Virus (NDV) vector platform expressing stabilized antigens such as HexaPro spike protein. Its lead candidate CVAX-01 targets COVID-19 and is in Phase 2 clinical testing, while the broader NDV platform supports a pipeline of respiratory and pandemic-preparedness vaccines licensed to international manufacturers in Thailand, Vietnam, Brazil, and Mexico.

Product overview

CastleVax is a clinical-stage vaccine company with a platform-plus-products architecture. The core technology is the Newcastle Disease Virus (NDV) vaccine platform, which produces live attenuated mucosal vaccines. The primary product is CVAX-01, a next-generation intranasal COVID-19 vaccine, alongside NDV-HXP-S (an alternative COVID-19 formulation). The company also has licensed products (Patria in Mexico, HXP-GPOVac in Thailand) and a robust pipeline including bivalent RSV+HMPV and Norovirus mucosal vaccines, plus a broader pandemic preparedness program targeting multiple viral pathogens.

Differentiator

Problem solved

Functional benefit

Brands

  • CVAX-01: Next-generation intranasal COVID-19 vaccine candidate using Newcastle Disease Virus (NDV) vector technology with HexaPro spike protein.
  • NDV-HXP-S

Products and services

  • CVAX-01 Next-generation, live, attenuated, Newcastle Disease Virus (NDV)-vectored intranasal COVID-19 vaccine candidate expressing a stabilized SARS-CoV-2 spike protein using HexaPro technology. Designed to elicit mucosal immunity and protect against SARS-CoV-2 breakthrough infection and transmission. Currently in Phase 2 clinical testing.
  • NDV-HXP-S COVID-19 booster vaccine utilizing Newcastle Disease Virus vector technology expressing stabilized SARS-CoV-2 spike protein with HexaPro technology. Available as live attenuated (intranasal/intramuscular) and inactivated (intramuscular) formulations. Demonstrated safety profile and low reactogenicity in multiple Phase 1, 2, and 3 clinical trials.
  • NDV Vaccine Platform Live, attenuated Newcastle Disease Virus (NDV)-based vaccine platform for developing mucosal vaccines. Enables rapid development of safe and highly immunogenic viral vectors using efficient mucosal delivery, with no pre-existing immunity in humans, flexible genome capacity up to 5kb, and bilipid membrane for foreign antigen incorporation. Supports monovalent, bivalent, or multivalent formulations. Licensed from Mount Sinai on an exclusive basis.
  • Patria (AVX/COVID-12) NDV-based COVID-19 vaccine developed by Laboratorio Avimex under license from CastleVax. Received Emergency Use Authorization in Mexico from COFEPRIS. Phase 3 results demonstrated effectiveness as a booster vaccine generating neutralizing antibodies comparable to WHO-approved vaccine comparator.
  • HXP-GPOVac NDV-HXP-S COVID-19 vaccine produced by Thailand's Government Pharmaceutical Organization (GPO). Inactivated formulation produced using egg-based technology. Received conditional approval for emergency use in Thailand as a booster for adults 18 years and older, marking the first domestically produced COVID-19 vaccine in Thailand.
  • Bivalent RSV+HMPV Vaccine Mucosal vaccine candidate targeting Respiratory Syncytial Virus (RSV) and Human Metapneumovirus (HMPV) in development as part of CastleVax's pipeline of respiratory virus mucosal vaccines.
  • Mucosal Norovirus Vaccine Mucosal vaccine candidate targeting Norovirus in development as part of CastleVax's pipeline of mucosal vaccines for respiratory and enteric pathogens.
  • Pandemic Preparedness Pipeline NDV platform engineered to express antigens from emerging and endemic viruses including SARS-CoV-2, RSV, HMPV, CMV, HBV, HCV, Arenaviruses (Lassa), Filoviruses (Ebola), Nipah Virus, Hendra Virus, Chikungunya, Rift Valley Fever, Hantavirus, and Highly Pathogenic Avian Influenza for pandemic preparedness.

Quantifiable outcome

  • In Phase 1/2 studies, NDV-HXP-S performed as well as Pfizer/BioNtech vaccine and outperformed AstraZeneca vaccine in immunogenicity
  • +3 more outcomes

Companies that use CastleVax

Customer profile

Named customers4 records

Segments3 records

Ideal customer profiles3 records

CastleVax technology and API

Technology

Technology focussed Yes

API detail

Has API
No
API docs
API detail

Core technology

AI maturity

App detail

Feature4 records

CastleVax partnerships and signals

Strategic signal

Partnerships

Seven partnerships are on record, tiered core and major.

  • AptarGroup, Inc.coreTechnology or IntegrationAptarGroup provides nasal vaccine delivery solutions (LuerVax® and Spray Divider™) utilized in CastleVax's Phase II clinical trial of CVAX-01. Their regulatory and technical expertise supports next-generation nasal vaccine delivery development.
  • Icahn School of Medicine at Mount SinaicoreStrategic or Co-development PartnerMount Sinai developed the NDV-vectored vaccine platform technology through scientists Peter Palese, Adolfo García-Sastre, Florian Krammer, and Weina Sun. Licensed exclusively to CastleVax for commercial development. Mount Sinai holds a financial interest in CastleVax and is represented on the Board of Directors.
  • The University of Texas at Austin (UT Austin)coreTechnology or IntegrationUT Austin developed the HexaPro spike protein technology (6 proline stabilizing mutations) used in CastleVax's vaccines. Licensed on a non-exclusive basis to CastleVax. The same team previously developed spike proteins used in several approved COVID-19 vaccines globally.
  • Laboratorio Avimex (Mexico)majorOEM/ Whitelabel/ Licensing PartnerAvimex licensed CastleVax's NDV-based vaccine technology to develop Patria® (AVX/COVID-12) COVID-19 vaccine. Completed Phase 3 clinical trials showing effectiveness as a booster comparable to WHO-approved vaccine. Received Emergency Use Authorization in Mexico. Project financed by Conacyt (Mexican National Council of Science and Technology).
  • Government Pharmaceutical Organization (GPO) ThailandmajorOEM/ Whitelabel/ Licensing PartnerGPO licensed the NDV-HXP-S vaccine technology for domestic production in Thailand. Completed Phase 3 clinical evaluation with 4,000 volunteers. Received conditional approval for emergency use - the first domestically produced COVID-19 vaccine in Thailand. Manufacturing capacity of 5-10 million doses annually.
  • Institute of Vaccines and Medical Biologicals (IVAC) VietnammajorOEM/ Whitelabel/ Licensing PartnerIVAC licensed the NDV-HXP-S vaccine (COVIVAC) for production in Vietnam. Phase 2 results showed higher concentration of neutralizing antibodies compared to AstraZeneca vaccine. Phase 3 clinical trials in planning.
  • PATHmajorStrategic or Co-development PartnerPATH served as connector, facilitator, and technical advisor for the international NDV-HXP-S vaccine consortium. With funding from CEPI, PATH supported consortium efforts aligned with advancing immunization equity. Supported vaccine development in Thailand, Vietnam, and Brazil.

Scale indicators7 records

Recent moves7 records

Expansion highlights5 records

CastleVax competitors and assessment

Company assessment

Others

  • Intravacc: Vaccine contract development and manufacturing organization with mucosal vaccine expertise and government/biodefense relationships analogous to CastleVax's BARDA-funded development model.

Direct peers

  • CyanVac: Clinical-stage vaccine developer using bovine and avian paramyxovirus vectors (closely related to NDV) for intranasal mucosal vaccines, including RSV and COVID-19 candidates. Directly comparable platform approach and mucosal delivery focus targeting respiratory pathogens.
  • Codagenix: Clinical-stage vaccine company using live-attenuated viral vector platforms (including intranasal formulations) to develop vaccines against influenza, RSV, and other respiratory viruses. Shares CastleVax's live-attenuated intranasal mucosal vaccine thesis.
  • Meissa Vaccines: Clinical-stage biotech developing intranasal live-attenuated vaccines for RSV and other respiratory viruses, with similar small team, mucosal immunity focus, and clinical-stage profile comparable to CastleVax.
  • FluGen: Developer of M2SR intranasal influenza vaccine, sharing CastleVax's intranasal respiratory vaccine positioning and clinical-stage development profile.

Emerging players

  • Vaxxinity: Clinical-stage biotech developing vaccines for infectious diseases and chronic conditions. CastleVax's Director of Clinical Operations previously led vaccine trials at Vaxxinity, reflecting overlapping talent pool and clinical operations approach.

Broad incumbents

  • Bharat Biotech: Large global vaccine manufacturer with multiple platform technologies (including intranasal and viral vector vaccines) serving LMIC markets, comparable to CastleVax's licensed manufacturing partners in India-adjacent emerging markets.
  • Novavax: Established commercial-stage vaccine developer with COVID-19 and influenza candidates using protein subunit and matrix-M adjuvant platforms. Competes with CastleVax for the same next-generation COVID-19 booster market.
  • Moderna: Dominant mRNA COVID-19 vaccine manufacturer and BARDA Project NextGen recipient, representing the entrenched standard-of-care comparator against which CastleVax's CVAX-01 is being tested.
  • BioNTech: mRNA vaccine leader with Pfizer-partnered COVID-19 vaccine that serves as the primary comparator and standard-of-care threat to CastleVax's intranasal COVID-19 booster strategy.

Market position

Strengths4 records

Weaknesses4 records

Competitive moat5 records

Key risks6 records

Key highlights6 records

Customer concentration

CastleVax social profiles

Digital presence

CastleVax compliance and trust

Trust signal

Compliance3 records

CastleVax financial estimates

Financial estimate

Revenue estimate

Valuation estimate

CastleVax leadership team

Management profile

Number of profiles

Profiles11 records

CastleVax funding detail

Funding detail

Funding overview

Funding rounds1 record

Investors1 record

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

CastleVax M&A and investment

M&A and investment

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about CastleVax

What does CastleVax do?

CastleVax is a clinical-stage vaccine platform company that develops and licenses mucosal (intranasal) vaccines built on the Newcastle Disease Virus (NDV) vector platform expressing stabilized antigens such as HexaPro spike protein. Its lead candidate CVAX-01 targets COVID-19 and is in Phase 2 clinical testing, while the broader NDV platform supports a pipeline of respiratory and pandemic-preparedness vaccines licensed to international manufacturers in Thailand, Vietnam, Brazil, and Mexico.

Is CastleVax a public or private company?

CastleVax is a private company. It is classified as corporate owned and is currently operating.

When was CastleVax founded?

CastleVax was founded in 2022. It employs 1 to 10 people.

Where is CastleVax based?

CastleVax is headquartered in New York, United States, in the North America region.

How does CastleVax make money?

Two revenue lines are on record. Vaccine Development and Licensing is the primary driver. The others are government Contracts and Grants.

Who are CastleVax's main competitors?

Intravacc is listed as an others. Direct peers are CyanVac, Codagenix, Meissa Vaccines and FluGen. Vaxxinity is listed as an emerging player. Broad incumbents are Bharat Biotech, Novavax, Moderna and BioNTech.

Does CastleVax have an API?

No public API is recorded for CastleVax.

What industry is CastleVax in?

CastleVax's product category is Biotechnology. Its primary akta.pro industry code is HLAAAEAD, Vaccine Technology Platforms (mRNA, viral vector, protein subunit, inactivated/live-attenuated, VLP, DNA), with a secondary code of HLAAAEAA, Prophylactic Human Vaccines (routine, pediatric, adult). Its NAICS code is 325412 and its SIC code is 2834.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales
Live signals
BioSpaceAptar’s Nasal Vaccine Delivery Solutions Featured in CastleVax Phase II Clinical Trial of an Intranasal COVID-19 Vaccine CandidateAptarGroup, Inc. announced that its nasal vaccine delivery solutions, LuerVax® and Spray Divider™, are being utilized in CastleVax's Phase II clinical trial of CVAX-01, a next-generation intranasal COVID-19 vaccine candidate. The Phase II study will evaluate around 200 U.S. adults, including high-risk individuals and those over 65, over six months to assess whether nasal delivery can provide strong mucosal immunity compared to an FDA-approved injectable mRNA vaccine. This collaboration positions Aptar as a partner supporting next-generation vaccine development through its regulatory and technical expertise.BioSpaceCastleVax Announces Initiation of a Phase 2 Study Evaluating Its Mucosally-delivered, Next Generation, COVID-19 Vaccine CandidateCastleVax announced the dosing of the first participant in a Phase 2 clinical study evaluating CVAX-01, its intranasal next-generation COVID-19 vaccine candidate, comparing it against an FDA-approved mRNA vaccine. The study will enroll approximately 200 U.S. adults previously vaccinated against COVID-19, evaluating safety, tolerability, and both systemic and mucosal immune responses over a 6-month follow-up period. The NDV-vectored vaccine platform was developed at Mount Sinai and licensed to CastleVax, with the vaccine already having received full regulatory approval in Thailand and Emergency Use Authorization in Mexico.School of Public HealthCEPI announces award to advance needle-free vaccine delivery technologyThe Coalition for Epidemic Preparedness and Innovations (CEPI) announced a $3.7 million award to Micron Biomedical to advance the development of a needle-free vaccine delivery button. This funding will support research combining Micron's microarray technology with CastleVax's rapid-response platform, using COVID-19 as an initial target pathogen. The technology aims to address vaccine access challenges in remote regions by enabling self-administered, refrigeration-free delivery.Pulse 2.0CastleVax: Mucosal Vaccine Platform Receives $34 Million AwardCastleVax received a $34 million BARDA Project NextGen award to develop its mucosal COVID-19 vaccine CVAX-01. The award funds a Phase 2b efficacy study enrolling 10,000 participants, half receiving the intranasal vaccine and half a licensed vaccine. The study aims to show reduced breakthrough infections.Business Wire BlogCastleVax Inc. Receives $34 Million from BARDA to Continue Advancing Intranasal NDV-based COVID-19 Vaccine into Phase 2b Clinical Efficacy TestingCastleVax Inc. received a $34 million award from the Biomedical Advanced Research and Development Authority (BARDA) to advance its intranasal NDV-based COVID-19 vaccine candidate, CVAX-01, into Phase 2b clinical efficacy testing. The funding supports a study involving 10,000 participants designed to evaluate the vaccine's ability to reduce SARS-CoV-2 breakthrough infections compared to standard systemic vaccines. This development builds upon previous authorizations in Mexico and Thailand for related formulations of the vaccine.ReutersUS government to fund up to $500 mln for studies on oral, nasal COVID vaccinesThe U.S. Department of Health and Human Services announced up to $500 million for mid-stage trials of oral and nasal COVID vaccines. BARDA awarded $453 million to Vaxart for its oral vaccine and about $34 million to Castlevax and $40 million to Cyanvac for intranasal candidates. Each trial will enroll 10,000 volunteers.ContractpharmaNeedle-Free Vaccines: Leading Innovation in Drug DeliveryA panel discussion on needle-free vaccine delivery featured Jurata, CastleVax, and Stanford's Dr. Jacobson, covering thin film, mucosal, and microarray patch technologies. The speakers noted that vaccines lead demand for non-parenteral routes, with methods depending on the pathogen and potential for broader applications like acne treatment.Genetic Literacy ProjectWhen will needle-free COVID vaccines arrive in the US?The US federal government is funding two companies, Codagenix and CastleVax, with nearly $20 million to test mucosal COVID vaccines. Five such vaccines are currently in use in China, India, Iran, Indonesia, Morocco, and Russia, with more in trials.HHS.govProject NextGen Selects Initial Vaccine Candidates and Awards Over $500 Million to Advance Development of Vaccines and TherapeuticsHHS announced initial next-generation vaccine candidates and over $500 million in awards for Project NextGen, accelerating planning for Phase 2b clinical trials. The funding includes $8.5 million to CastleVax, $10 million to Codagenix, and $10 million to Gritstone Bio, with additional support for testing and delivery technologies.